Page last updated: 2024-09-04

dx 8951 and elacridar

dx 8951 has been researched along with elacridar in 1 studies

Compound Research Comparison

Studies
(dx 8951)
Trials
(dx 8951)
Recent Studies (post-2010)
(dx 8951)
Studies
(elacridar)
Trials
(elacridar)
Recent Studies (post-2010) (elacridar)
7318152848119

Protein Interaction Comparison

ProteinTaxonomydx 8951 (IC50)elacridar (IC50)
ATP-dependent translocase ABCB1Homo sapiens (human)0.4427
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)0.2852

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boven, E; Hoogsteen, IJ; Kohlhagen, G; Maliepaard, M; Pinedo, HM; Pommier, Y; Scheffer, GL; Scheper, RJ; Schlüper, HM; van Hattum, AH1

Other Studies

1 other study(ies) available for dx 8951 and elacridar

ArticleYear
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
    British journal of cancer, 2002, Sep-09, Volume: 87, Issue:6

    Topics: Acridines; Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Isoquinolines; Membrane Glycoproteins; Mice; Mice, Nude; Mutation; Neoplasm Proteins; Neoplasms, Experimental; Ovarian Neoplasms; Tetrahydroisoquinolines; Tetraspanin 29; Tetrazolium Salts; Thiazoles; Topoisomerase I Inhibitors; Tumor Cells, Cultured

2002